Prospective Melanoma Database
NCT02884362 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 10000
Last updated 2016-08-31
Summary
In research on melanoma, translational research is the essential link between basic research and clinical research by facilitating the passage between discovery and improvement in the quality of patients care.That is the reason why it is very important to collect, and centralize clinical and biological data of patients with melanoma.
The aim of the project is to provide to scientific community a structured, mixed clinical and biological database, unique in France, in order to insure accessibility to clinical data.
Conditions
Interventions
- OTHER
-
clinical biological data collection on melanoma
collection and centralization of clinical and biological data of patients with melanoma
Sponsors & Collaborators
-
Institut Claudius Regaud
lead OTHER
Principal Investigators
-
Nicolas MEYER, MD PHD · Institut claudius regaud Toulouse ONCOPOLE
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-01-31
- Primary Completion
- 2026-01-31
- Completion
- 2026-06-30
Countries
- France
Study Locations
More Related Trials
-
Blocking TNF to Potentiate the ICI-dependent Immune Awakening in Melanoma
NCT05867004 ·Status: RECRUITING
-
Study of Risk Factors and Clinical Characterization of Rapidly Growing Melanoma
NCT02879474 ·Status: UNKNOWN
-
Multicentric Cohort of Melanoma Patients in Ile de France Area
NCT00839410 ·Status: COMPLETED
-
Optimization of the Patient Care Pathway in Immuno-oncology
NCT03329755 ·Status: COMPLETED ·Phase: NA
-
Evaluation of Sphingolipids as Predictive Biomarkers of Immune Checkpoint Inhibitor Response in Melanoma Patients
NCT03627026 ·Status: COMPLETED ·Phase: NA
-
Predictive Clinical Features for Response to Adjuvant Immunotherapy in Stage II,III and IV Resected Melanoma
NCT05527795 ·Status: RECRUITING
-
TNF-Inhibitor as Immune Checkpoint Inhibitor for Advanced MELanoma
NCT03293784 ·Status: COMPLETED ·Phase: PHASE1
-
Exploratory Interventional Study of Prognostic Serum Biomarkers of Cancer Progression
NCT05426317 ·Status: UNKNOWN ·Phase: NA
-
Tracing Dissemination of Melanoma Cells in Healthy Tissues
NCT02854124 ·Status: COMPLETED
-
Clinical Outcomes and Biomarkers in Patients With Stage 0-IV Melanoma in Real Clinical Practice
NCT05402059 ·Status: UNKNOWN
-
Triple BRAFinh/MEKinh /antiPD1 Combined Therapy in Patients With BRAF Mutated Melanoma With Central Nervous System Metastasis
NCT05510466 ·Status: UNKNOWN
-
French Clinical Datbase of Melanoma Patients (RIC-Mel)
NCT03315468 ·Status: RECRUITING
-
Characterisation of T Lymphocytes, NK Cells and Macrophages in Melanoma Patients
NCT01336270 ·Status: COMPLETED
-
Definition of an Immune Signature Predictive of Anti-PD1 (Programmed Death-1) Antibody in the Treatment of Advanced Melanoma
NCT02938728 ·Status: UNKNOWN
-
Identification of Metabolic Phenotypes Associated With Melanoma Metastasis
NCT06400550 ·Status: RECRUITING
-
Serial Tumour Biopsies and Blood Biomarkers in Melanoma
NCT04493723 ·Status: RECRUITING
-
Neoadjuvant L19IL2/L19TNF- Pivotal Study
NCT02938299 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases
NCT02374242 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Patients With Inoperable Metastatic Cutaneous Melanoma
NCT00896480 ·Status: COMPLETED ·Phase: PHASE2
-
The Impact of Melanoma and Drug Treatment in the Real World
NCT03379454 ·Status: COMPLETED
-
Gene Expression Profiles and ctDNA for Risk Stratification in Patients With Melanoma
NCT06566404 ·Status: NOT_YET_RECRUITING
-
Generation of an Artificial Intelligence Algorithm Based on the Analysis of Melanoma Peri-scar Dermatoheliosis, as a Predictive Factor of Response to Anti-PD-1
NCT05856565 ·Status: RECRUITING
-
Expression of IL4 Induced Gene 1 in Patients With Cutaneous Melanoma: Value in Prognosis and/or in Predictive Response to Immune Checkpoint Inhibitors
NCT04253080 ·Status: COMPLETED ·Phase: NA
-
A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma
NCT00942162 ·Status: COMPLETED ·Phase: PHASE2
-
Intratumoral Application of L19IL2 in Patients With Malignant Melanoma
NCT01253096 ·Status: COMPLETED ·Phase: PHASE2